IDEAYA Secures Exclusive Global License for Biocytogen’s First-In-Class BsADC, B7H3/PTK7 Topo-I Payload (IDE034), Validating Biocytogen’s Ren...
First and only NMPA-approved treatment for patients with CIDP in China Third approval for efgartigimod franchise in China demonstrating Zai Lab&rs...
Perceptive eClinical, part of Perceptive Group, is pleased to announce the launch of ClinPhone 5, a ground-breaking new Randomization and Trial Supply Mana...
ResQ Pharma, Inc., a Chicago-based pharmaceutical company developing and commercializing innovative drug therapies, announced that it has received a P...
Alteogen Inc. (KOSDAQ:196170) announced that the company has entered into an exclusive license agreement with Daiichi Sankyo (TSE: 4568). Under the terms o...
Gilead Sciences, Inc. (Nasdaq: GILD) announced the upcoming presentation of HIV research findings at the International Congress on Drug Therapy in HIV Infe...
With a renewed focus on drug prices, fast-track approvals, and ‘America First’ production, industry experts warn pharma to brace for Tr...
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, announced that the United States (U.S.) Food and D...
The Global Health Innovative Technology (GHIT) Fund announced a total investment of approximately JPY 578 million (USD 4.0 million1) in four...
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced the pivotal Phase 3 study design following successful alignment with the U.S. Food and...
The European Medicines Agency has approved Dupixent (dupilumab) to treat eosinophilic esophagitis (EoE) in children as young as one year of age. Specifical...
Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral t...
Headway, the company building a new mental healthcare system, announced its participation in the Aligned Innovation initiative, a groundbreaking cross-indu...
BioCity Biopharma (BioCity) announced late-breaking results of the 2-SUCCEED clinical trial of SC0062, a selective endothelin receptor type A (ETA) an...
© 2024 Biopharma Boardroom. All Rights Reserved.
